Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Leukemia

Free Subscription 22.09.2025 1 Am J Hematol 8 Ann Hematol 1 Biochem Pharmacol 1 Bone Marrow Transplant 5 Br J Haematol 1 Eur J Haematol 1 Int J Hematol 2 J Virol 1 Leukemia 1 Oncogene 1 PLoS One

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Am J Hematol

1. VENANZI A, Santi A, Zambello R, Giordano C, et al
   Independent Origin of Hairy Cell Leukemia (HCL) From Co-Occurring Clonal Hematopoiesis (CH).
   Am J Hematol. 2025 Sep 13. doi: 10.1002/ajh.70060.
   PubMed         Abstract available
   
   

   
   Ann Hematol

2. REN Z, De Moerloose B, Lammens T
   Prime-time for LncRNA signatures in acute myeloid leukemia?
   Ann Hematol. 2025 Sep 18. doi: 10.1007/s00277-025-06616.
   PubMed         Abstract available
   
   
3. AZZA E, Ben Othmen A, Bahri M, Hsasna R, et al
   T-cell acute lymphoblastic leukemia: therapeutic outcomes in adolescents and young adults.
   Ann Hematol. 2025 Sep 18. doi: 10.1007/s00277-025-06597.
   PubMed         Abstract available
   
   
4. LI H, Gu Y, Zhao X, Ding G, et al
   Comparative longitudinal analysis of pulmonary function post-pediatric Allo-HSCT: benign vs. malignant diseases and early predictors.
   Ann Hematol. 2025;104:4201-4211.
   PubMed         Abstract available
   
   
5. HERLING M, Angelucci E, Benoit TM, Rivoli G, et al
   Durable outcomes with manageable safety leading to prolonged survival with tagraxofusp for treatment-naive patients with blastic plasmacytoid dendritic cell neoplasm: real world results from a European Named Patient Program.
   Ann Hematol. 2025;104:4121-4131.
   PubMed         Abstract available
   
   
6. WANG Y, Zhang Y, Liu J, Jiang Y, et al
   Next-generation Bruton tyrosine kinase inhibitors and degraders in the treatment of B-cell malignancies: advances and challenges.
   Ann Hematol. 2025;104:3929-3941.
   PubMed         Abstract available
   
   
7. BUCHRITS S, Trieman G, Giladi O, Hofstetter L, et al
   Infectious complications in CLL/SLL patients receiving Bruton's Tyrosine Kinase inhibitors - systematic review and meta-analysis of randomized controlled trials.
   Ann Hematol. 2025;104:3903-3915.
   PubMed         Abstract available
   
   
8. ERNST J, Reinsch S, Mentzel HJ, Milde T, et al
   Successful treatment with mesenchymal stromal cells-Frankfurt am Main in a pediatric patient with steroid-refractory and ruxolitinib-refractory acute gastrointestinal graft-versus-host disease.
   Ann Hematol. 2025;104:4237-4243.
   PubMed         Abstract available
   
   
9. CIMINO G, Caridi M, Cardinali V, Sciabolacci S, et al
   Venetoclax plus azacitidine as genetic-driven bridge-to-transplant therapy for IDH2-mutated acute myeloid leukaemia (AML) refractory to intensive chemotherapy: proof-of-concept case reports.
   Ann Hematol. 2025;104:4267-4271.
   PubMed         Abstract available
   
   

   
   Biochem Pharmacol

10. TU G, Wu Q, Yuan Y, Jiang Q, et al
    DNA damage agents trigger iNKT cell-mediated elimination of AML cells through activation of NF-kappaB/HLA-DRB6/CD1d pathway.
    Biochem Pharmacol. 2025;241:117174.
    PubMed         Abstract available
    
    

    
    Bone Marrow Transplant

11. RU Y, Chen J, Ferhat AT, Einsele H, et al
    Haploidentical versus matched unrelated donor hematopoietic cell transplantation for adult patients with refractory/relapsed acute lymphoblastic leukemia: a study from the Global Committee and the Acute Leukemia Working Party of the European Society f
    Bone Marrow Transplant. 2025 Sep 15. doi: 10.1038/s41409-025-02708.
    PubMed         Abstract available
    
    

    
    Br J Haematol

12. ROLLES B, Chatain N, Gorg R, Vieri M, et al
    ZIP10 as a potential therapeutic target in acute myeloid leukaemia.
    Br J Haematol. 2025;207:767-779.
    PubMed         Abstract available
    
    
13. ZU Y, Yue X, Zhan X, Liu X, et al
    Secondary malignancies after chronic myeloid leukaemia upon TKI treatment: Population trends and outcomes.
    Br J Haematol. 2025;207:834-841.
    PubMed         Abstract available
    
    
14. KOSYDAR S, Archibald WJ, Hampel PJ, Call TG, et al
    The role of imaging studies in predicting time to first treatment and overall survival in high-count monoclonal B-cell lymphocytosis.
    Br J Haematol. 2025;207:860-868.
    PubMed         Abstract available
    
    
15. CHENG CN, Yang YN, Yeh YH, Chen JS, et al
    The impact of secondary hypogammaglobulinaemia in children with acute lymphoblastic leukaemia receiving maintenance chemotherapy.
    Br J Haematol. 2025;207:892-901.
    PubMed         Abstract available
    
    
16. LI X, Zhou Q, Hao X, Cao C, et al
    Targeting NLRP1-CCL8 axis in the leukaemic niche suppresses AML via inhibition of PI3K-AKT signalling.
    Br J Haematol. 2025;207:789-801.
    PubMed         Abstract available
    
    

    
    Eur J Haematol

17. SRINIVASAN T, Mallik N, Sachdeva MUS, Bose P, et al
    CD48 Is a Robust Marker and a Useful Addition for Assessment of Measurable Residual Disease in T-Cell Acute Lymphoblastic Leukemia.
    Eur J Haematol. 2025 Sep 13. doi: 10.1111/ejh.70035.
    PubMed         Abstract available
    
    

    
    Int J Hematol

18. TOMINAGA R, Fujiwara SI, Honda S, Yokoyama D, et al
    Significance of the tendency for relative bradycardia during induction therapy for acute myeloid leukemia.
    Int J Hematol. 2025 Sep 18. doi: 10.1007/s12185-025-04070.
    PubMed         Abstract available
    
    

    
    J Virol

19. CUI Z, Shen K, Xu M, Yao Y, et al
    Avian leukosis virus p15 interacts with interferon regulatory factor 7 to antagonize the cGAS-STING signaling pathway and promote viral replication.
    J Virol. 2025;99:e0038025.
    PubMed         Abstract available
    
    
20. DUCHATEAU T, Afonso PV, Journo C
    Untangling the causes of geographical disparities in the clinical outcome of HTLV-1 infection: a critical perspective on the contribution of viral genetic diversity.
    J Virol. 2025;99:e0060125.
    PubMed         Abstract available
    
    

    
    Leukemia

21. POLLYEA D, Kerre T, Deeren D, Beguin Y, et al
    Downregulation of MICA/MICB improves cell persistence and clinical activity of NKG2DL CAR T-cells in patients with relapsed or refractory acute myeloid leukemia or myelodysplastic neoplasia.
    Leukemia. 2025 Sep 15. doi: 10.1038/s41375-025-02767.
    PubMed         Abstract available
    
    

    
    Oncogene

22. BOVE G, Babaei M, Bueno-Costa A, Amin S, et al
    METTL16-mediated inhibition of MXD4 promotes leukemia through activation of the MYC-MAX axis.
    Oncogene. 2025 Sep 14. doi: 10.1038/s41388-025-03563.
    PubMed         Abstract available
    
    

    
    PLoS One

23. ZHANG J, Zhou W, Liu Y, Hu C, et al
    TRIM6 affects the prognosis of acute myeloid leukemia through the PI3K/AKT signaling pathway and is associated with immune infiltration.
    PLoS One. 2025;20:e0329560.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Leukemia is free of charge.